Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Ara-C and Idarubicin in Relapsed/Refractory AML
NCT02249091Phase 2Completed
- Sponsor
- GSO Global Clinical Research
- Start
- Sep 2014
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in acute myeloid leukemia (AML), sponsored by GSO Global Clinical Research. Started Sep 2014; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02249091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249091.